close 74% jaeinvestorite kontodest jääb selle teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. CFD-d on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb selle teenusepakkuja juures CFD-dega kauplemisel kahjumisse. Palume teil kaaluda, kas CFD-de toimimine on teile arusaadav ja kas te olete valmis võtma riski, mis suure tõenäosusega on kahjumlik.
Change languageEesti
Ülevaade

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

LLY

749.85

+1.61%↑

JNJ

177.08

-0.6%↓

ABBV

210.45

+0.22%↑

UNH

348.61

+8.84%↑

NVO

54.26

-0.09%↓

Kodu・Aktsiate loetelu・Galectin Therapeutics Inc
Search

Galectin Therapeutics Inc

Avatud

SektorTervishoid

4.9 7.46

Osta

Hinna uuendus 9. sept 2025, 18:56 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.6

Max

4.9

Põhinäitajad

By Trading Economics

Sissetulek

2.1M

-7.5M

Kasumimarginaal

-33,241.667

Töötajad

15

EBITDA

4.5M

-5.7M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+28.48% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

13. nov 2025

Turustatistika

By TradingEconomics

Turukapital

29M

274M

Eelmine avamishind

-2.56

Eelmine sulgemishind

4.9

Uudiste sentiment

By Acuity

32%

68%

112 / 371 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bullish Evidence

1.19 / 1.33 Toetus ja vastupanu

Galectin Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

8. sept 2025, 23:59 UTC

Omandamised, ülevõtmised, äriostud

Anglo American Is in Talks to Buy Teck Resources, Bloomberg Says

DJ

Loe

8. sept 2025, 22:02 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4 Billion AI Deal With Nebius

DJ

Loe

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Eightco Holdings Stock Surges as Dan Ives Joins Board Amid Crypto Push

DJ

Loe

8. sept 2025, 17:01 UTC

Suurimad hinnamuutused turgudel

Tron Shares Rise After New Investment From Bravemorning

DJ

Loe

8. sept 2025, 16:14 UTC

Suurimad hinnamuutused turgudel

Beyond Air Shares Climb on FDA Orphan Drug Designation for Brain Cancer Treatment

DJ

Loe

8. sept 2025, 16:13 UTC

Suurimad hinnamuutused turgudel

Dianthus Shares Whipsaw on Strong Trial Results, Safety Concerns

DJ

Loe

8. sept 2025, 23:12 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

8. sept 2025, 23:12 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

8. sept 2025, 23:12 UTC

Market Talk

Infratil's New Bull Likes Exposure to Growing Infrastructure Businesses -- Market Talk

DJ

Loe

8. sept 2025, 22:56 UTC

Market Talk

Worst May Be Over for New Zealand Retailers -- Market Talk

DJ

Loe

8. sept 2025, 22:23 UTC

Market Talk

Ebos's Near-Term Earnings Outlook Dims -- Market Talk

DJ

Loe

8. sept 2025, 21:51 UTC

Market Talk

AT&T Backs Outlook After EchoStar Spectrum Purchase -- Market Talk

DJ

Loe

8. sept 2025, 21:47 UTC

Suurimad hinnamuutused turgudel

Microsoft Signs $17.4B AI Deal With Nebius

DJ

Loe

8. sept 2025, 21:33 UTC

Omandamised, ülevõtmised, äriostud

This Quantum Pure Play Is Going Public. What Infleqtion Does Differently, Says Its CEO. -- Barrons.com

DJ

Loe

8. sept 2025, 21:20 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Plans to Respond on or Before Sept 15 >MEG.T

DJ

Loe

8. sept 2025, 21:19 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Special Committee and Board Will Evaluate Revised Strathcona Offer >MEG.T

DJ

Loe

8. sept 2025, 21:18 UTC

Omandamised, ülevõtmised, äriostud

MEG Energy Acknowledges Strathcona's Intention to Revise Offer

DJ

Loe

8. sept 2025, 20:50 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

8. sept 2025, 19:33 UTC

Market Talk

Oil Futures Gain Despite Planned OPEC+ Output Increases -- Market Talk

DJ

Loe

8. sept 2025, 19:22 UTC

Market Talk

U.S. Natural Gas Futures Settle Higher -- Market Talk

DJ

Loe

8. sept 2025, 19:02 UTC

Market Talk

Dollar Lukewarm Amid Data Hiatus Ahead of August CPI -- Market Talk

DJ

Loe

8. sept 2025, 18:24 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

DJ

Loe

8. sept 2025, 18:24 UTC

Market Talk

Weaker Argentine Peso Profitable for Grain Producers -- Market Talk

DJ

Loe

8. sept 2025, 17:29 UTC

Market Talk

Mexican Inflation Seen Little Changed in August -- Market Talk

DJ

Loe

8. sept 2025, 16:59 UTC

Market Talk
Omandamised, ülevõtmised, äriostud

SpaceX Spectrum Acquisition Will Create More Satellite Connection Supply, Verizon CEO Says -- Market Talk

DJ

Loe

8. sept 2025, 16:36 UTC

Market Talk

Crude Futures Hold Gains After OPEC+ Output Decision -- Market Talk

DJ

Loe

8. sept 2025, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

8. sept 2025, 16:16 UTC

Tulu

Strategy Stock May Not Ever Make It Into the S&P 500 Index -- Barrons.com

DJ

Loe

8. sept 2025, 16:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

DJ

Loe

8. sept 2025, 16:04 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Galectin Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

28.48% tõus

12 kuu keskmine prognoos

Keskmine 6 USD  28.48%

Kõrge 6 USD

Madal 6 USD

Põhineb 1 Wall Streeti analüütiku instrumendi Galectin Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

1 ratings

1

Osta

0

Hoia

0

Müü

Põhineb 1 analüütiku instrumendi Galectin Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.19 / 1.33Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bullish Evidence

Recent bullish events outweigh bearish events.

Keskpikk perspektiiv

Weak Bullish Evidence

Recent bullish events outweigh bearish events.

Pikk perspektiiv

Weak Bearish Evidence

Bearish events outweigh bullish events.

Sentiment

By Acuity

112 / 371 Pingereas Tervishoid

Uudiste sentiment

Languse märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Galectin Therapeutics Inc

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

749.85

↑ +1.61%

JNJ

Johnson and Johnson

177.08

↓-0.6%

ABBV

AbbVie Inc

210.45

↑ +0.22%

UNH

UnitedHealth Group Inc

348.61

↑ +8.84%

NVO

Novo Nordisk A-S

54.26

↓-0.09%
help-icon Live chat